美国医药产业创新政策环境研究及对中国的启示——基于阿法依泊汀研发的实证研究  

American Innovation Policy Environment of Pharmaceutical Industry and Its Enlightenment to China——An Empirical Study on R&D of Epoetin Alfa

作　　者：颜建周[1] 董心月 陈永法[1] 王梦媛[1] 邵蓉[1] 

机构地区：[1]中国药科大学国家药物政策与医药产业经济研究中心,江苏南京211198

出　　处：《中国科技论坛》2018年第1期182-188,共7页Forum on Science and Technology in China

基　　金：国家社会科学基金重大项目"我国创新药物政策环境研究"(15ZDB167);工信部课题"实现我国医药产业由大变强的路径研究"(X153011)

摘　　要：本文在梳理美国医药产业创新政策环境的基础上,采用案例剖析法,以美国安进制药公司的阿法依泊汀(EPO)为实证研究对象,系统梳理EPO的发展历程,并深入探讨美国医药产业创新政策对关键环节的具体作用机制及实施效果。结果表明,安进公司在完善的医药创新政策环境下实现了EPO的完整创新。相比之下,中国应当积极构建完善的创新政策环境。同时,进一步加强知识产权保护力度,提高创新研发积极性;加强技术、知识产权资本化意识,为创新研发提供多元化融资渠道。This paper presented the American innovation policy environment of pharmaceutical industry. On this basis, case analysis method was used and epoetin alfa（EPO） was taken as the object of empirical study, to discuss the development process of EPO, as well as the action mechanism and implementation effect of the innovation policy environment of American pharmaceutical industry. The results show that Amgen succeeded in achieving complete creation under pharmaceutical innovation policy environment. So China should perfect actively innovation enviornment. Furthermore, the intellectual property protection（IPR） should be strengthened to boost inde- pendent R＆D positivity, and the awareness of capitalization of technology should be raised to provide diversified ways of raising funds.

关 键 词：医药产业 研发 创新 政策环境 EPO 

分 类 号：R951[医药卫生—药学]